Suchergebnisse - Vivek Subbiah

Treffer weiter einschränken
  1. 1
    Chronic Lung Disease after Premature Birth

    Chronic Lung Disease after Premature Birth von Vivek Subbiah

    Veröffentlicht 2008
    Volltext
    Carta
    Zu den Favoriten
    Gespeichert in:
  2. 2
    The next generation of evidence-based medicine

    The next generation of evidence-based medicine von Vivek Subbiah

    Veröffentlicht 2023
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  3. 3
    Tissue-agnostic cancer therapies: promise, reality, and the path forward

    Tissue-agnostic cancer therapies: promise, reality, and the path forward von Vivek Subbiah

    Veröffentlicht 2025
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  4. 4
    Challenging Standard-of-Care Paradigms in the Precision Oncology Era

    Challenging Standard-of-Care Paradigms in the Precision Oncology Era von Vivek Subbiah, Razelle Kurzrock

    Veröffentlicht 2018
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  5. 5
    Managing Cancer Care during the COVID-19 Pandemic and Beyond

    Managing Cancer Care during the COVID-19 Pandemic and Beyond von Omar Alhalabi, Vivek Subbiah

    Veröffentlicht 2020
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  6. 6
    Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i>

    Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> von Vivek Subbiah, Razelle Kurzrock

    Veröffentlicht 2023
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Tumor-agnostic drug development in dMMR/MSI-H solid tumors

    Tumor-agnostic drug development in dMMR/MSI-H solid tumors von Deepak Bhamidipati, Vivek Subbiah

    Veröffentlicht 2023
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  8. 8
    Clinical development and management of adverse events associated with FGFR inhibitors

    Clinical development and management of adverse events associated with FGFR inhibitors von Vivek Subbiah, Srđan Verstovšek

    Veröffentlicht 2023
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  9. 9
    Advances in Targeting RET-Dependent Cancers

    Advances in Targeting RET-Dependent Cancers von Vivek Subbiah, Gilbert J. Cote

    Veröffentlicht 2020
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  10. 10
    Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy

    Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy von Mohamed A. Gouda, Vivek Subbiah

    Veröffentlicht 2023
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  11. 11
    Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors

    Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors von Mohamed A. Gouda, Vivek Subbiah

    Veröffentlicht 2023
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  12. 12
    Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers

    Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers von Mohamed A. Gouda, Vivek Subbiah

    Veröffentlicht 2023
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  13. 13
    Clinical Development of BRAF plus MEK Inhibitor Combinations

    Clinical Development of BRAF plus MEK Inhibitor Combinations von Vivek Subbiah, Christina S. Baik, John M. Kirkwood

    Veröffentlicht 2020
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  14. 14
    From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm

    From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm von Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

    Veröffentlicht 2020
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  15. 15
    Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives

    Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives von Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

    Veröffentlicht 2017
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  16. 16
    The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

    The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians von Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

    Veröffentlicht 2020
    Volltext
    Editorial
    Zu den Favoriten
    Gespeichert in:
  17. 17
    State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers

    State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers von Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

    Veröffentlicht 2020
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  18. 18
    The abscopal effect in patients with cancer receiving immunotherapy

    The abscopal effect in patients with cancer receiving immunotherapy von Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

    Veröffentlicht 2023
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  19. 19
    From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies?

    From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? von Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

    Veröffentlicht 2025
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  20. 20
    The emerging role of PI3K inhibitors for solid tumour treatment and beyond

    The emerging role of PI3K inhibitors for solid tumour treatment and beyond von Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

    Veröffentlicht 2023
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: